JP2025507939A - がんワクチンおよびその使用方法 - Google Patents

がんワクチンおよびその使用方法 Download PDF

Info

Publication number
JP2025507939A
JP2025507939A JP2024552335A JP2024552335A JP2025507939A JP 2025507939 A JP2025507939 A JP 2025507939A JP 2024552335 A JP2024552335 A JP 2024552335A JP 2024552335 A JP2024552335 A JP 2024552335A JP 2025507939 A JP2025507939 A JP 2025507939A
Authority
JP
Japan
Prior art keywords
hla
allele
interleukin
gene
human cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507939A5 (https=
Inventor
ウィリアム ブイ． ウィリアムズ
ミゲル ロペス－ラゴ
マーカス ダニエル ラッハー
Original Assignee
ブリアセル セラピューティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブリアセル セラピューティクス コーポレイション filed Critical ブリアセル セラピューティクス コーポレイション
Publication of JP2025507939A publication Critical patent/JP2025507939A/ja
Publication of JP2025507939A5 publication Critical patent/JP2025507939A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024552335A 2022-03-03 2023-03-02 がんワクチンおよびその使用方法 Pending JP2025507939A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263316251P 2022-03-03 2022-03-03
US63/316,251 2022-03-03
US202263415475P 2022-10-12 2022-10-12
US63/415,475 2022-10-12
PCT/US2023/014337 WO2023167973A1 (en) 2022-03-03 2023-03-02 Cancer vaccines and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025507939A true JP2025507939A (ja) 2025-03-21
JP2025507939A5 JP2025507939A5 (https=) 2026-02-26

Family

ID=85772911

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552335A Pending JP2025507939A (ja) 2022-03-03 2023-03-02 がんワクチンおよびその使用方法

Country Status (8)

Country Link
US (1) US20250186568A1 (https=)
EP (1) EP4486371A1 (https=)
JP (1) JP2025507939A (https=)
CN (1) CN119053337A (https=)
AU (1) AU2023227477A1 (https=)
CA (1) CA3254024A1 (https=)
IL (1) IL315361A (https=)
WO (1) WO2023167973A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240156869A1 (en) * 2021-03-12 2024-05-16 T-Cure Bioscience, Inc. Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy
WO2025171109A1 (en) 2024-02-07 2025-08-14 Briacell Therapeutics Corp. Cancer vaccines expressing post-translational modified antigens and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
DE19832840C1 (de) * 1998-07-21 2000-06-08 Kerkmann Tucek Aida Mittel zur Immuntherapie von Tumorerkrankungen
US7807186B2 (en) * 2007-01-17 2010-10-05 University Of Maryland, Baltimore County Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
WO2017147600A1 (en) 2016-02-25 2017-08-31 Briacell Therapeutics Corp. Whole-cell cancer vaccines and methods for selection thereof

Also Published As

Publication number Publication date
AU2023227477A1 (en) 2024-09-19
IL315361A (en) 2024-11-01
US20250186568A1 (en) 2025-06-12
EP4486371A1 (en) 2025-01-08
CN119053337A (zh) 2024-11-29
WO2023167973A1 (en) 2023-09-07
CA3254024A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
KR102557834B1 (ko) 신규의 세포 태그의 발현
KR102308798B1 (ko) 다양한 암의 면역요법 치료에서의 사용을 위한 펩티드, 펩티드의 조합 및 골격
US10258653B2 (en) IL-12 immunotherapy for cancer
JP2019510488A (ja) 抗腫瘍免疫を誘導するための、腫瘍関連抗原の複数のエピトープを発現するウイルスベクター
CN111511911A (zh) 表达特异性地识别人间皮素的细胞表面分子、il-7和ccl19的免疫活性细胞
MD3430037T2 (ro) Celule T transfectate și receptori de celule T pentru utilizare în imunoterapie împotriva cancerelor
JP2025507939A (ja) がんワクチンおよびその使用方法
CN111632135A (zh) 靶向nkg2d的嵌合抗原受体t细胞在治疗前列腺癌中的应用、治疗前列腺癌的药物
CN111655278A (zh) 免疫治疗性癌症控制中的混合谱系激酶结构域样蛋白
WO2020212986A1 (en) Siglec-based chimeric polypeptides and uses thereof
CN110115758A (zh) Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用
US11613567B2 (en) Modulators of notch signaling and methods of use thereof
HK40117271A (zh) 癌症疫苗及其使用方法
WO2025171109A1 (en) Cancer vaccines expressing post-translational modified antigens and methods of use thereof
JP2024516882A (ja) 構築物と免疫刺激性化合物の共発現
EP4687956A1 (en) Methods for enhancing the immunogenicity of cellular vaccines
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
EP4328239A1 (en) Immunotherapeutics based on magea1-derived epitopes
CN121406676A (zh) 用于免疫细胞衔接剂的核酸和药物组合物
JP2024538169A (ja) Ｎｄｃ８０抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
JP2024539273A (ja) Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
CN118043066A (zh) 构建体和免疫刺激性化合物的共表达
JP2025523003A (ja) Ｖｃｙ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
EP4313124A1 (en) Therapeutic combination for treating cancer
CN119894923A (zh) 包含tmigd2共刺激结构域的嵌合抗原受体及其相关使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260217